University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Katherine Van Loon, MD, MPH

Katherine Van Loon, MD, MPH

Assistant Clinical Professor, UCSF; Director, Global Cancer Program, Helen Diller Family Comprehensive Cancer Center

Cancer Center Program Memberships

Cancer Control

Education

Duke University    B.S.    05/00    Biology
Yale University    M.P.H.    05/02    Health Policy
Medical College of Georgia    M.D.    05/06    Medicine
Beth Israel Deaconess, Harvard Medical School    Intern    06/07    Internal Medicine
Beth Israel Deaconess, Harvard Medical School    Resident    06/09    Internal Medicine
University of California, San Francisco    Fellow    06/12    Oncology
 


Professional Experience

  • 2012-present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF
  • 2011-2012
    Non-ACGME Fellow, Division of Hematology/Oncology, UCSF
  • 2009-2011
    ACGME Fellow, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2013
    NANETS Clinical Investigator Scholarship
  • 2013
    AHRQ K12 PARTNERS Program Scholar
  • 2012
    Young Investigator Award, ASCO Conquer Cancer Foundation
  • 2008
    Yale/Johnson & Johnson Physician Scholar in International Health, South Africa
  • 2008
    Nomination by Harvard Medical School Class of 2008 for Excellence in Teaching
  • 2002
    Dean’s Prize for Outstanding MPH Thesis, Yale University
  • 2001
    Weinerman Fellowship for Social Justice, Yale University
  • 2000
    Graduation with Distinction in Biology, Duke University
  • 2000
    Howard Hughes Undergraduate Fellowship in Neuroscience, Duke University

Selected Publications

  • 1.Ortiz, G.M., Wellons, M., Brancato, J., Vo, H.T., Zinn, R.L., Clarkson, D.E., Van Loon, K., Bonhoeffer, S., Miralles, G.D., Montefiori, D., Bartlett, J.A., Nixon, D.F. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences. 2001. 98(23):13288-93.
  • 2. Van Loon, K., Lindegger, G. Informed consent in clinical trials: Perceptions and experiences of a sample of South African researchers. Health South Africa Gesondheid. 2009. 14(1):81-87.
  • 3.Van Loon, K., Venook, A.P. Adjuvant treatment of colon cancer: what is next? Current Opinion in Oncology. July 2011. 23(4): 403-9.
  • 4.Van Loon, K., Gill, R.M., McMahon, P., et al. 20q- Clonality in a Case of Oral Sweet Syndrome and Myelodysplasia. American Journal of Clinical Pathology. 2012. 137(2): 310-5.
  • 5.Van Loon, K., Venook, A.P. Metastatic Colorectal Cancer: A Curable Disease. Oncology. March 13, 2012. 26(3): 275-2.
  • 6.Van Loon, K., Venook, A.P. Adjuvant therapy in stage II colon cancer: Pain not justified by the gain. JNCCN. November 1, 2012. 10(11):1379-86.
  • 7.Van Loon, K., Wigler, D., Niedzwiecki, D. et al. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: Findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer. January 2013. (Epub ahead of print).
  • 8.Van Loon, K., Espinoza, A.M., Fogelman, D.R., et al. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. (submitted).

Books
  • 1. Thompson, R.J., and Van Loon, K. (2002). “Mental disorders.” In T.J. Boll (Series Ed.) & S.B. Johnson, N.W. Perry, & R.H. Rozensky (Vol. Eds.), Healthcare Psychology Handbook: Vol. 3. Disease Applications (143-72). Washington, DC: American Psychological Association.
  • 2. Van Loon, K., Tempero, M. (in press). “Pancreatic Cancer.” In Expert Clinical Perspective on the Diagnosis & Management of Cancer. Oxford, UK.